Cargando…

Mesenchymal Bone Marrow Cell Therapy in a Mouse Model of Chagas Disease. Where Do the Cells Go?

BACKGROUND: Chagas disease, resulting from infection with the parasite Trypanosoma cruzi (T. cruzi), is a major cause of cardiomyopathy in Latin America. Drug therapy for acute and chronic disease is limited. Stem cell therapy with bone marrow mesenchymal cells (MSCs) has emerged as a novel therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jasmin, Jelicks, Linda A., Koba, Wade, Tanowitz, Herbert B., Mendez-Otero, Rosalia, Campos de Carvalho, Antonio C., Spray, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521704/ https://www.ncbi.nlm.nih.gov/pubmed/23272265 http://dx.doi.org/10.1371/journal.pntd.0001971

Ejemplares similares

Cell Therapy in Chagas Disease
por: Campos de Carvalho, Antonio C., et al.
Publicado: (2009)

Optimized labeling of bone marrow mesenchymal cells with superparamagnetic iron oxide nanoparticles and in vivo visualization by magnetic resonance imaging
por: Jasmin, et al.
Publicado: (2011)

Correction: optimized labeling of bone marrow mesenchymal cells with superparamagnetic iron oxide nanoparticles and in vivo visualization by magnetic resonance imaging
por: Jasmin, et al.
Publicado: (2011)

Perspectives on Adipose Tissue, Chagas Disease and Implications for the Metabolic Syndrome
por: Nagajyothi, Fnu, et al.
Publicado: (2009)

Aspirin Treatment of Mice Infected with Trypanosoma cruzi and Implications for the Pathogenesis of Chagas Disease
por: Mukherjee, Shankar, et al.
Publicado: (2011)

Chagas' disease and AIDS
por: Vaidian, Anil K, et al.
Publicado: (2004)

High Fat Diet Modulates Trypanosoma cruzi Infection Associated Myocarditis
por: Nagajyothi, Fnu, et al.
Publicado: (2014)

Chagas Disease Has Now Gone Global
por: Tanowitz, Herbert B., et al.
Publicado: (2011)

Pathogenesis of Chagas Cardiomyopathy: Role of Inflammation and Oxidative Stress
por: Machado, Fabiana S., et al.
Publicado: (2013)

COVID-19 Vaccination. Where Are We and Where Should We Go?
por: Peña-Otero, David
Publicado: (2022)

Mesenchymal Stromal Cells’ Therapy for Polyglutamine Disorders: Where Do We Stand and Where Should We Go?
por: Barros, Inês, et al.
Publicado: (2020)

Coronary Microvascular Disease in Chronic Chagas Cardiomyopathy Including an Overview on History, Pathology, and Other Proposed Pathogenic Mechanisms
por: Rossi, Marcos A., et al.
Publicado: (2010)

Preconditioning of Rat Bone Marrow-Derived Mesenchymal Stromal Cells with Toll-Like Receptor Agonists
por: Evaristo-Mendonça, Fabiana, et al.
Publicado: (2019)

Scoping review of brucellosis in Cameroon: Where do we stand, and where are we going?
por: Laine, Christopher G., et al.
Publicado: (2020)

Erratum to “Preconditioning of Rat Bone Marrow-Derived Mesenchymal Stromal Cells with Toll-Like Receptor Agonists”
por: Evaristo-Mendonça, Fabiana, et al.
Publicado: (2020)

Commentary: Round and round the mesenchymal stromal cells go; where they stop, we hope to know
por: Matte, Gregory S., et al.
Publicado: (2021)

Where are they going? Directed cell movement in morphogenesis
por: Zimmermann, Frank
Publicado: (2001)

Where to Go: Breaking the Symmetry in Cell Motility
por: Huang, Sui
Publicado: (2016)

The Einstein-Brazil Fogarty: A decade of synergy
por: Nosanchuk, Joshua D., et al.
Publicado: (2015)

Where is APC going?
por: Mimori-Kiyosue, Yuko, et al.
Publicado: (2001)

Where are we going?
por: Pawl, Ronald P.
Publicado: (2010)

Where is science going?
por: Planck, Max Karl Ernst Ludwig, et al.
Publicado: (1933)

Where is crystallography going?
por: Grimes, Jonathan M., et al.
Publicado: (2018)

The OAI and OAI-PMH: where to go from here?
por: Carl Lagoze and Herbert Van de Sompel
Publicado: (2004)

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go
por: Lv, Meng, et al.
Publicado: (2012)

Dermatology: Where are We Coming from and Where are We Going to?
por: van de Kerkhof, Peter C. M.
Publicado: (2014)

Review of Preclinical and Clinical Studies of Bone Marrow-Derived Cell Therapies for Intracerebral Hemorrhage
por: Rosado-de-Castro, Paulo Henrique, et al.
Publicado: (2016)

FKBP Ligands—Where We Are and Where to Go?
por: Kolos, Jürgen M., et al.
Publicado: (2018)

Correction: Where to Go: Breaking the Symmetry in Cell Motility
Publicado: (2016)

Durotaxis and negative durotaxis: where should cells go?
por: Ji, Congcong, et al.
Publicado: (2023)

Neutrino Masses and Mixing: Where We Stand and Where We are Going
por: Gonzalez-Garcia, M.C.
Publicado: (2002)

13 Ebola virus: where does it come from and where is it going?
por: Murphy, Frederick A., et al.
Publicado: (1998)

Tracking stem cells with superparamagnetic iron oxide nanoparticles: perspectives and considerations
por: Jasmin,, et al.
Publicado: (2017)

The future of high-grade glioma: Where we are and where are we going
por: Rhun, Emilie Le, et al.
Publicado: (2015)

The Clusmy Child: Where Are We and Where Are We Going?
por: Hadders-Algra, Mijna, et al.
Publicado: (2003)

European HEPnet: where we are and where we are going
por: Carpenter, B E, et al.
Publicado: (1990)

Iron health: where are we and where are we going?
por: Gotardo, Glória Ines Beal
Publicado: (2011)

Hip Arthroscopy: Where We Are, and Where We Are Going
por: Park, Myung Sik, et al.
Publicado: (2015)

Bioactive Glasses: Where Are We and Where Are We Going?
por: Baino, Francesco, et al.
Publicado: (2018)

Diabetic cardiomyopathy: where we are and where we are going
por: Lee, Wang-Soo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7bnpcuplg7hm57q0hiqoon2ij0